Given that some deafness-causing mutations are known to be localized to alternative exons (i.e. R643X in PCDH15[60] and R500X in TRIC[61]), understanding the regulation of alternative exon choice in the inner ear is expected to create therapeutic opportunities for the prevention of deafness. Here, MARVELD2 is linked to deafness.